David J. Bier You can find my written testimony here. The video below gives my prepared remarks: Chairman McClintock, Ranking Member Jayapal, and distinguished...
Tad DeHaven President Trump’s latest financial disclosures do not prove that he personally timed investments around his administration’s decision-making. That’s not the point, though. ...
With some simple logic and using Hobbes’s own presuppositions and arguments, we can internally critique Hobbes’s argument for the state, namely, that the state...
Despite the fact that the government owes firms refunds due to Trump’s tariffs being declared illegal, companies are turning down the opportunity in fear...
Colleen Hroncich When Valeria Oquendo—known to her students simply as Miss V—finished her education degree in Florida, her plan was to become a public...
The current strain of illiberalism running through western thought conflicts with the themes of individual liberty and liberalism that also came from western thinkers....
Dr. Wanjiru Njoya argues that Rothbard’s political philosophy is not a sideshow to his economics but its essential second pillar, and that this integrated...
Murray Rothbard is one of the all-time greats in Austrian economics and libertarianism. When studying his achievements, we immediately see that Rothbard is a...
Patrick G. Eddington Early this morning, Senate Majority Leader John Thune (R‑SD) secured cloture on S.4344, Senator Tom Cotton’s (R‑AR) bill to extend Section...
Clark Packard Department of Agriculture Secretary Brooke Rollins made headlines last week when she called rising fertilizer prices an “overarching economic pending disaster” before...
Jeffrey Miron New research uses regional per capita tax burdens in 1780s France to examine the relationship between tax burdens and rioting. It finds...
Andrew Gillen With federal deficits at high and unsustainable levels, there is an urgent need to find ways to cut federal spending. Fortunately, new...
Jeffrey A. Singer Two recent Wall Street Journal editorials argue that the Food and Drug Administration’s (FDA) “inexplicable” rejection of RP1, an immunotherapy for melanoma, may cost...
Join The Exclusive Subscription Today And Get Premium Articles For Free
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!